NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) announced it received first place in the Healthcare category at the BOLD Awards VII Gala held March 27, 2026, in Barcelona, recognizing its leadership in exosome-based therapies for central nervous system injuries. The company also provided a corporate update highlighting its selection by a panel of global industry leaders.
In addition, NurExone reported plans to engage Investor Brand Network (IBN), subject to TSX Venture Exchange approval, to support investor awareness efforts beginning April 1, 2026. The engagement will include distribution of news and updates across more than 5,000 outlets, with a monthly fee of $6,500 under a one-year agreement aimed at strengthening market visibility and long-term shareholder value.
NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.
This announcement is important because it underscores NurExone's recognition by industry peers and its proactive steps to increase investor visibility through a targeted communications partnership. The BOLD Awards honor innovative companies that are shaping the future, and winning first place in the Healthcare category validates NurExone's approach to exosome-based therapies. Meanwhile, engaging IBN—a platform that reaches over 5,000 outlets—could significantly broaden the company's exposure to potential investors and stakeholders.
For more details, the full press release is available at https://ibn.fm/cWtqT. Additional information about NurExone can be found on its website at https://nurexone.com/.
